In female NOD mice, AG490 at 1 mg/mouse intraperitoneally, three times weekly for 5 weeks and then weekly for 5 weeks, lowered diabetes incidence when treatment began at 4 or 8 weeks of age. In a separate cohort treated for 5 weeks from age 4 weeks, pancreatic insulitis scores did not significantly differ from vehicle controls. The incidence result therefore did not coincide with a demonstrated reduction in insulitis in that histology experiment. [4]
In mouse endotoxemia, AG490 pretreatment at 10 mg/kg intraperitoneally reduced serum TNF and TNF in lung and spleen, but not in liver or heart. Separate cohorts showed improved survival at 0.5 or 10 mg/kg. In polymicrobial sepsis induced by cecal ligation and puncture, 5 mg/kg AG490 given at 12 h, or at both 24 and 36 h after surgery, improved survival with antibiotic and fluid support. These studies report pharmacodynamic and survival endpoints rather than pharmacokinetic exposure. [3]
Pretreatment in mouse endotoxemia
Animal study · Male C57BL/6J mice, 6–8 weeks old; LPS endotoxemia (6 mg/kg, i.p.) [3]
AG490 pretreatment reduced serum TNF at 10 mg/kg and reduced TNF in lung and spleen, with no reported reduction in liver or heart. Separate survival cohorts showed improved survival at 0.5 and 10 mg/kg.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Single pretreatment, 30 min before LPS
- Vehicle
- Ethanol; Methods wording is “20 mM ethanol”; final administered solvent fraction and injection volume are not established
- TNF dose response
- Model: Male C57BL/6J mice, 6–8 weeks old; LPS endotoxemia (6 mg/kg, i.p.)
- Treatment course: TNF collected 90 min after LPS
- Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
- Survival cohorts
- Model: Male C57BL/6J mice, 6–8 weeks old; LPS endotoxemia (6 mg/kg, i.p.)
- Treatment course: Survival followed for 2 weeks
- Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
Methods and source locations
Compound reported in the paper: AG-490; Compound label in the paper: AG490
Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.
Figure 4A-C and legend; Results: JAK2 inhibition prevented serum HMGB1 and rescued mice; Methods: Animals, Chemicals, Cytokine analyses
Serum and tissue TNF 90 min after LPS: TNF ELISA; tissue TNF normalized to protein; n=6/group, *p<0.05 versus LPS; approximate values are author-reported — Figure 4A-B; Results paragraph describing Figure 4
Survival after endotoxemia: Logrank test; n=20 animals/group; monitored 2 weeks, no late deaths reported; figure displays the first week — Figure 4C and legend
TNF dose response · Figure 4A-B and legend
Survival cohorts · Figure 4C and legend
Delayed treatment in polymicrobial sepsis
Animal study · Male C57BL/6J mice, 6–8 weeks old; cecal ligation and puncture (CLP) [3]
AG490 administered after CLP improved survival in two delayed-treatment schedules. All animals received antibiotic and fluid support described in the CLP methods.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Vehicle
- Ethanol; Methods wording is “20 mM ethanol”; final administered solvent fraction and injection volume are not established
- 12 h start
- Model: Male C57BL/6J mice, 6–8 weeks old; cecal ligation and puncture (CLP)
- Frequency: Once, 12 h after CLP
- Treatment course: One dose; survival monitored 2 weeks
- Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
- 24 h start
- Model: Male C57BL/6J mice, 6–8 weeks old; cecal ligation and puncture (CLP)
- Frequency: At 24 and 36 h after CLP
- Treatment course: Two doses; survival monitored 2 weeks
- Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
Methods and source locations
Compound reported in the paper: AG-490; Compound label in the paper: AG490
Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.
Figure 5C-D and legend; Results final paragraph before Figure 4; Methods: Cecal ligation and puncture
Survival after established CLP sepsis: Logrank test; n=10/group for 12 h schedule, n=22/group for 24/36 h schedule; monitored 2 weeks with no late deaths reported — Figure 5C-D and legend; Results CLP paragraph
12 h start · Figure 5C and Results CLP paragraph
24 h start · Figure 5D and Results CLP paragraph
Diabetes prevention in NOD mice
Animal study · Female NOD/LtJ mice starting at 4 or 8 weeks of age [4]
AG490 lowered diabetes incidence when treatment began at 4 or 8 weeks of age. The study defined diabetes as blood glucose >250 mg/dl on two consecutive tests 24 h apart.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Three times/week for 5 weeks, then once/week for 5 additional weeks
- Treatment course
- 10-week dosing schedule; incidence comparison at week 30
- Vehicle
- Sterile DMSO diluted with sterile PBS; final fraction and volume not reported
- Treatment beginning at 4 weeks
- Model: Female NOD/LtJ mice starting at 4 or 8 weeks of age; 4-week cohort
- Reported limits: Final DMSO fraction and injection volume not reported; no AG490 exposure measurements.
- Treatment beginning at 8 weeks
- Model: Female NOD/LtJ mice starting at 4 or 8 weeks of age; 8-week cohort
- Reported limits: Final DMSO fraction and injection volume not reported; no AG490 exposure measurements.
Methods and source locations
Compound reported in the paper: AG-490; Compound label in the paper: AG490
Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.
Figure 1A-B and legend; Results: AG490 prevents development of autoimmune diabetes; Methods: Mice, Compound, Administration of AG490
Diabetes-free survival through week 30: Kaplan-Meier comparison as reported; blood glucose measured by ACCU-CHEK; no curve percentages inferred — Figure 1A-B and legend; Methods: Administration of AG490
Treatment beginning at 4 weeks · Figure 1A and legend; Methods: Compound and Administration
Treatment beginning at 8 weeks · Figure 1B and legend; Methods: Compound and Administration
Pancreatic insulitis after AG490 treatment
Animal study · Female NOD mice, treatment started at 4 weeks; separate histology cohort [4]
AG490 did not significantly change pancreatic insulitis scores in this separate cohort, despite the lower diabetes incidence observed in the prevention cohorts.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Three times/week for 5 consecutive weeks
- Treatment course
- Sacrificed at week 10, described as one week after last injection
- Vehicle
- Sterile DMSO diluted with sterile PBS; final fraction and volume not reported
- Five-week treatment and week-10 histology
- Model: Female NOD mice, treatment started at 4 weeks; separate histology cohort
- Reported limits: Final DMSO fraction and injection volume not reported; no AG490 exposure measurements.
Methods and source locations
Compound reported in the paper: AG-490; Compound label in the paper: AG490
Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.
Figure 4A and legend; Results: Administration of AG490 does not diminish leukocyte infiltration; Methods: Histology and immunofluorescence histochemistry, Compound
Pancreatic leukocyte infiltration/insulitis score: Two blinded investigators; average scores, ≥150 islets/group in two sections 100 µm apart; n=5 mice/group; score 0=intact/pre-insulitis, 1=<50% infiltration, 2=>50% infiltration — Figure 4A and legend; Methods: Histology
Five-week treatment and week-10 histology · Figure 4A legend; Methods: Compound